© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 13, 1154-1158,
July 7, 1999
© 1999 Oxford University Press
REPORTS |
Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular Carcinoma
Affiliations of authors: A. Tannapfel, C. Wittekind (Institute of Pathology), M. Wasner, K. Krause, J. Mössner, K. Engeland (Department of Internal Medicine II), F. Geissler, J. Hauss (Department of Surgery II), University of Leipzig, Germany. A. Katalinic, Institute of Cancer Epidemiology, University of Lübeck, Germany.
Correspondence to: Andrea Tannapfel Institute of Pathology, University of Leipzig, Liebigstrasse 26, 04103 Leipzig, Germany (e-mail: tana{at}medizin.uni-leipzig.de).
BACKGROUND: The protein p73, the first identified homologue of the tumor suppressor gene p53 (also known as TP53), has been shown to induce apoptosis (programmed cell death), but its function in tumor development has not been established. This study was undertaken to investigate the expression of p73 in liver tissue of patients with hepatocellular carcinoma (HCC) and to determine whether this expression has any impact on prognosis. METHODS: In situ hybridization and immunohistochemistry for the detection of p73 RNA transcripts and protein, respectively, were performed in tissues from 193 patients with curatively (R0-) resected HCC. Patients receiving liver transplantation were excluded. The results obtained were analyzed with respect to their association with pathohistologic stage, Edmondson grade, p53 expression status and several histopathologic factors of possible prognostic value, and, finally, with patient survival. RESULTS: RNA transcripts encoding p73 were detected by in situ hybridization in tumor cells but not in stromal, endothelial, or inflammatory cells or in cholangiocytes. Transcripts were also found occasionally in non-neoplastic hepatocytes. By immunohistochemistry, we detected p73 protein in 61 (32%) of the 193 carcinomas examined. Positive immunohistochemical staining was confined to the cell nucleus. Univariate survival analysis showed that p73 expression status was statistically significantly related to prognosis (two-sided P<.0001). Patients with p73-positive tumors had a poorer prognosis than those with p73-negative carcinomas. Multivariate Cox survival analysis identified the age of the patient, p73 expression status, co-existing cirrhosis, and Edmondson grade as independent prognostic factors. CONCLUSION: The protein p73 is overexpressed by a subset of HCCs and could serve as a useful indicator of prognosis in patients with this disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. K. Ahmad, X. Altuna, J. P. Lopez, Y. An, J. Wang-Rodriguez, V. R. Juneja, J. S. Chen, M. J. Arandazi, J. Aguilera, J. P. Harris, et al. p73 Expression and Function in Vestibular Schwannoma Arch Otolaryngol Head Neck Surg, July 1, 2009; 135(7): 662 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tannapfel, K. John, N. Mise, A. Schmidt, S. Buhlmann, S. M. Ibrahim, and B. M. Putzer Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73 Carcinogenesis, January 1, 2008; 29(1): 211 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bozzetti, R. Nizzoli, A. Musolino, E. M. Martella, P. Crafa, C. A. Lagrasta, R. Camisa, A. Bonati, P. Lunghi, and A. Ardizzoni p73 and p53 Pathway in Human Breast Cancers J. Clin. Oncol., April 10, 2007; 25(11): 1451 - 1453. [Full Text] [PDF]
|
|
|
|
|
|
G. Dominguez and F. Bonilla In Reply J. Clin. Oncol., April 10, 2007; 25(11): 1453 - 1454. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Liu, K. Y.-K. Chan, A. N.-Y. Cheung, X.-Y. Liao, T.-W. Leung, and H. Y.-S. Ngan Expression of {Delta}Np73 and TAp73{alpha} Independently Associated with Radiosensitivities and Prognoses in Cervical Squamous Cell Carcinoma. Clin. Cancer Res., July 1, 2006; 12(13): 3922 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dominguez, J. M. Garcia, C. Pena, J. Silva, V. Garcia, L. Martinez, C. Maximiano, M. E. Gomez, J. A. Rivera, C. Garcia-Andrade, et al. {Delta}TAp73 Upregulation Correlates With Poor Prognosis in Human Tumors: Putative In Vivo Network Involving p73 Isoforms, p53, and E2F-1 J. Clin. Oncol., February 10, 2006; 24(5): 805 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Guan and Y Chen Aberrant expression of {Delta}Np73 in benign and malignant tumours of the prostate: correlation with Gleason score J. Clin. Pathol., November 1, 2005; 58(11): 1175 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Li, J. Zhu, and J. Y. J. Wang Ectopic Expression of p73{alpha}, but Not p73{beta}, Suppresses Myogenic Differentiation J. Biol. Chem., January 21, 2005; 280(3): 2159 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tomkova, A. Belkhiri, W. El-Rifai, and A. I. Zaika p73 Isoforms Can Induce T-Cell Factor-Dependent Transcription in Gastrointestinal Cells Cancer Res., September 15, 2004; 64(18): 6390 - 6393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huynh Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma Carcinogenesis, August 1, 2004; 25(8): 1485 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stiewe, S. Tuve, M. Peter, A. Tannapfel, A. H. Elmaagacli, and B. M. Putzer Quantitative TP73 Transcript Analysis in Hepatocellular Carcinomas Clin. Cancer Res., January 15, 2004; 10(2): 626 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. M. Moll The Role of p63 and p73 in Tumor Formation and Progression: Coming of Age Toward Clinical Usefulness: Commentary re: F. Koga et al., Impaired p63 Expression Associates with Poor Prognosis and Uroplakin III Expression in Invasive Urothelial Carcinoma of the Bladder. Clin. Cancer Res., 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in Human Normal and Tumor Tissues: Loss of p73{alpha} Expression Is Associated with Tumor Progression in Bladder Cancer. Clin. Cancer Res., 9: 5642-5651, 2003. Clin. Cancer Res., November 15, 2003; 9(15): 5437 - 5441. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guan, H.-X. Peng, B. Yu, and Y. Lu p73 Overexpression and Angiogenesis in Human Colorectal Carcinoma Jpn. J. Clin. Oncol., May 1, 2003; 33(5): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Tannapfel, F Sommerer, M Benicke, A Katalinic, D Uhlmann, H Witzigmann, J Hauss, and C Wittekind Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut, May 1, 2003; 52(5): 706 - 712. [Abstract] [Full Text]
|
|
|
|
|
|
T. Stiewe, J. Stanelle, C. C. Theseling, B. Pollmeier, M. Beitzinger, and B. M. Putzer Inactivation of Retinoblastoma (RB) Tumor Suppressor by Oncogenic Isoforms of the p53 Family Member p73 J. Biol. Chem., April 11, 2003; 278(16): 14230 - 14236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stiewe, S. Zimmermann, A. Frilling, H. Esche, and B. M. Putzer Transactivation-deficient {Delta}TA-p73 Acts as an Oncogene Cancer Res., July 1, 2002; 62(13): 3598 - 3602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Strano, G. Fontemaggi, A. Costanzo, M. G. Rizzo, O. Monti, A. Baccarini, G. Del Sal, M. Levrero, A. Sacchi, M. Oren, et al. Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities J. Biol. Chem., May 17, 2002; 277(21): 18817 - 18826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stiewe, C. C. Theseling, and B. M. Putzer Transactivation-deficient Delta TA-p73 Inhibits p53 by Direct Competition for DNA Binding. IMPLICATIONS FOR TUMORIGENESIS J. Biol. Chem., April 12, 2002; 277(16): 14177 - 14185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-F. Sun p73 Overexpression Is a Prognostic Factor in Patients with Colorectal Adenocarcinoma Clin. Cancer Res., January 1, 2002; 8(1): 165 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gaiddon, M. Lokshin, J. Ahn, T. Zhang, and C. Prives A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain Mol. Cell. Biol., March 1, 2001; 21(5): 1874 - 1887. [Abstract] [Full Text]
|
|
|
|
|
|
A Tannapfel, M Benicke, A Katalinic, D Uhlmann, F Kockerling, J Hauss, and C Wittekind Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver Gut, November 1, 2000; 47(5): 721 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Levrero, V De Laurenzi, A Costanzo, J Gong, J. Wang, and G Melino The p53/p63/p73 family of transcription factors: overlapping and distinct functions J. Cell Sci., January 5, 2000; 113(10): 1661 - 1670. [Abstract] [PDF]
|
|